Absci Corp (ABSI) - Total Assets
Based on the latest financial reports, Absci Corp (ABSI) holds total assets worth $244.99 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See ABSI total equity for net asset value and shareholders' equity analysis.
Absci Corp - Total Assets Trend (2019–2024)
This chart illustrates how Absci Corp's total assets have evolved over time, based on quarterly financial data.
Absci Corp - Asset Composition Analysis
Current Asset Composition (December 2024)
Absci Corp's total assets of $244.99 Million consist of 62.7% current assets and 37.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 19.3% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $44.88 Million | 21.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Absci Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Absci Corp market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Absci Corp's current assets represent 62.7% of total assets in 2024, a decrease from 70.1% in 2019.
- Cash Position: Cash and equivalents constituted 19.3% of total assets in 2024, down from 67.2% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 21.0% of total assets, an increase from 1.0% in 2019.
- Asset Diversification: The largest asset category is intangible assets at 21.0% of total assets.
Absci Corp Competitors by Total Assets
Key competitors of Absci Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.06 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.31 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥819.45 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.16 Billion |
Absci Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.89 | 5.63 | 7.25 |
| Quick Ratio | 5.89 | 5.63 | 7.25 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $145.29 Million | $123.46 Million | $63.14 Million |
Absci Corp - Advanced Valuation Insights
This section examines the relationship between Absci Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.64 |
| Latest Market Cap to Assets Ratio | 1.62 |
| Asset Growth Rate (YoY) | -1.7% |
| Total Assets | $213.61 Million |
| Market Capitalization | $345.85 Million USD |
Valuation Analysis
Above Book Valuation: The market values Absci Corp's assets above their book value (1.62x), reflecting positive investor sentiment about the company's future prospects.
Slight Asset Contraction: Absci Corp's assets decreased by 1.7% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Absci Corp (2019–2024)
The table below shows the annual total assets of Absci Corp from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $213.61 Million | -1.70% |
| 2023-12-31 | $217.30 Million | -32.31% |
| 2022-12-31 | $321.01 Million | -24.68% |
| 2021-12-31 | $426.19 Million | +381.20% |
| 2020-12-31 | $88.57 Million | +354.88% |
| 2019-12-31 | $19.47 Million | -- |
About Absci Corp
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to design differentiated antibody therapeutics. Its preclinical development programs include ABS-101 for the treatment of inflammatory bowel disease; ABS-201 for treating androgenic alopecia; ABS-301 for the treat… Read more